Can Infliximab Serve As a New Therapy for Neuropsychiatric Symptoms? Publisher Pubmed



Rahmatidehkordi F^{1, 2, 3} ; Birang N⁴ ; Jalalian MN⁵ ; Tamtaji Z⁶ ; Dadgostar E^{7, 8} ; Aschner M⁹ ; Shafiee Ardestani M¹⁰ ; Jafarpour H¹¹ ; Mirzaei H¹² ; Nabavizadeh F^{2, 3} ; Tamtaji OR^{2, 3}
Source: Naunyn-Schmiedeberg's Archives of Pharmacology Published:2025

Abstract

Neuropsychiatric disorders present a global challenge to public health. Mechanisms associated with neuropsychiatric disorders etiology include apoptosis, oxidative stress, and neuroinflammation. Tumor necrosis factor alpha, an inflammatory cytokine, mediates pathophysiology of neuropsychiatric disorders. Therefore, its inhibition by infliximab might afford a valuable target for intervention. Infliximab is commonly used to treat inflammatory diseases, including ulcerative colitis, Crohn’s disease, and rheumatoid arthritis. Recently, it has been shown that infliximab improves cognitive dysfunction, depression, anxiety, and life quality. Here, we review contemporary knowledge supporting the need to further characterize infliximab as a potential treatment for neuropsychiatric disorders. © The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature 2024.